Profile data is unavailable for this security.
About the company
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
- Revenue in USD (TTM)23.74bn
- Net income in USD3.93bn
- Incorporated1986
- Employees61.00k
- LocationDanaher Corp2200 Pennsylvania Ave NW Ste 800WWASHINGTON 20037-1731United StatesUSA
- Phone+1 (202) 828-0850
- Fax+1 (202) 828-0860
- Websitehttps://www.danaher.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medtronic PLC | 32.58bn | 3.93bn | 116.06bn | 95.00k | 30.44 | 2.42 | 17.61 | 3.56 | 2.97 | 2.97 | 24.66 | 37.39 | 0.3609 | 2.03 | 5.51 | 342,915.80 | 4.38 | 4.57 | 4.92 | 5.14 | 65.53 | 66.75 | 12.14 | 13.49 | 1.61 | 12.10 | 0.3665 | 80.58 | 3.64 | 1.16 | -2.18 | -4.56 | 6.95 | 6.65 |
| Boston Scientific Corporation | 15.91bn | 1.79bn | 123.69bn | 48.00k | 69.43 | -- | 42.34 | 7.77 | 1.21 | 1.21 | 10.73 | -- | -- | -- | -- | 331,458.30 | -- | 2.50 | -- | 2.91 | 69.01 | 68.84 | 11.24 | 6.47 | -- | 6.06 | -- | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Stryker Corp | 21.97bn | 3.59bn | 138.47bn | 52.00k | 38.96 | 6.88 | 29.93 | 6.30 | 9.33 | 9.33 | 57.08 | 52.86 | 0.5368 | 1.56 | 6.27 | 422,576.90 | 8.77 | 6.60 | 10.76 | 7.84 | 63.88 | 63.99 | 16.34 | 13.13 | 1.22 | -- | 0.4345 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
| Danaher Corp | 23.74bn | 3.93bn | 175.02bn | 61.00k | 45.73 | 3.41 | 28.30 | 7.37 | 5.30 | 5.24 | 32.05 | 71.03 | 0.2821 | 3.39 | 6.11 | 389,213.10 | 4.67 | 5.93 | 5.19 | 6.56 | 59.26 | 58.79 | 16.57 | 19.11 | 1.01 | 21.31 | 0.2546 | 14.33 | -10.33 | 6.98 | -32.50 | 11.85 | 16.10 | 11.32 |
| Intuitive Surgical, Inc. | 7.87bn | 2.24bn | 182.99bn | 13.68k | 82.59 | 11.74 | 66.35 | 23.26 | 6.22 | 6.22 | 21.81 | 43.75 | 0.4848 | 1.98 | 7.44 | 575,234.00 | 13.93 | 12.42 | 15.63 | 13.83 | 66.98 | 67.60 | 28.73 | 26.31 | 3.42 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
| Abbott Laboratories | 41.22bn | 5.77bn | 199.13bn | 114.00k | 34.70 | -- | 22.99 | 4.83 | 3.30 | 3.30 | 23.57 | -- | -- | -- | -- | 361,552.60 | -- | 7.72 | -- | 9.39 | 55.71 | 56.73 | 13.99 | 14.39 | -- | 28.32 | -- | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
| Thermo Fisher Scientific Inc | 42.37bn | 6.14bn | 210.33bn | 122.00k | 34.53 | 4.29 | 22.37 | 4.96 | 15.95 | 15.95 | 110.12 | 128.20 | 0.4292 | 4.62 | 4.68 | 347,295.10 | 6.28 | 7.79 | 7.36 | 9.11 | 40.98 | 44.94 | 14.62 | 16.76 | 1.26 | 24.40 | 0.4183 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 57.61m | 7.98% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 29.52m | 4.09% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 27.67m | 3.83% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 23.49m | 3.25% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 18.45m | 2.55% |
| Capital Research & Management Co. (International Investors)as of 30 Jun 2024 | 17.53m | 2.43% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 16.56m | 2.29% |
| Geode Capital Management LLCas of 30 Jun 2024 | 13.18m | 1.83% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 9.17m | 1.27% |
| T. Rowe Price Investment Management, Inc.as of 30 Jun 2024 | 7.94m | 1.10% |
